References
- Verma IM, Naldini, L, Kafri, T, et al. Gene therapy: promises, problems and prospects. In: Boulyjenkov V, Berg K, Christen Y, editors. Genes and resistance to disease. Berlin Heidelberg: Springer; 2000. P. 147–157. doi:10.1007/978-3-642-56947-0_13
- Ribeil J, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. . New England Journal of Medicine. 2017;376(9):848–855.
- Pearson SD. Effectiveness methods to determine value-based prices for potential cures: what are the options? Value Health. 2019;22(6):655–659.
- Cure sickle cell initiative | advancing research in sickle cell disease | cure sickle cell. curesickle.org. https://curesickle.org/. Published. 2021 2021 Jun 24.
- Gonçalves GAR, Paiva RMA. Gene therapy: advances, challenges and perspectives. Einstein (Sao Paulo). Einstein (Sao Paulo, Brazil). 2017;15(3):369–375.
- Dunbar CE. 2021. A plethora of gene therapies for hemoglobinopathies. . Nat Med. 202–204; 27,  10.1038/s41591-021-01235-7.
- Morgan R, Gray D, Lomova A, et al. Hematopoietic stem cell gene therapy: progress and lessons learned. cell stem cell. Cell Stem Cell. 2017;21(5):574–590.
- Yu K, Natanson H, Dunbar C. Gene editing of human hematopoietic stem and progenitor cells: promise and potential hurdles. Hum Gene Ther. Human Gene Therapy. 2016;27(10):729–740.
- Bernardo M, Aiuti A. The role of conditioning in hematopoietic stem-cell gene therapy. Hum Gene Ther. Human Gene Therapy. 2016;27(10):741–748.
- Quinn C, Young C, Thomas J, et al. Estimating the clinical pipeline of cell and gene therapies and their potential economic impact on the US healthcare system. Value Health. 2019;22(6):621–626.
- Centers for Disease Control and Prevention. Data & Statistics on Sickle Cell Disease. Centers for Disease Control and Prevention. Published August 31, 2016. Accessed 2020 Dec 18. https://www.cdc.gov/ncbddd/sicklecell/data.htm
- Wastnedge E, Waters D, Patel S, et al. The global burden of sickle cell disease in children under five years of age: a systematic review and meta-analysis. J. Glob Health. 2018;8(2):021103.
- Piel FB, Hay SI, Gupta S, et al. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality and interventions. . PLoS Med. 2013;10(7):e1001484.
- Sundd P, Gladwin MT, Novelli EM. Pathophysiology of Sickle Cell Disease. Annu Rev Pathol. 2019;14(1):263–292.
- American Society of Hematology; 2016. Rare patients with sickle cell disease live nearly twice as long as average. ; https://www.hematology.org/newsroom/press-releases/2016/rare-patients-with-sickle-cell-disease-live-nearly-twice-as-long-as-average. (Accessed: May 15, 2021).
- Lubeck D, Agodoa I, Bhakta N, et al. Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. JAMA Network Open. 2019 Nov 1; 2(11):e1915374.
- Paulukonis ST, Eckman JR, Snyder AB, et al. Defining sickle cell disease mortality using a population-based surveillance system, 2004 through 2008. Public Health Rep Wash DC. 1974;131(2):367–375.
- Lanzkron S, Carroll CP, Haywood C Jr., Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. 433021. 2013;128(2):110–116.
- Bradt P, Spackman E, Synnott PG, et al.Crizanlizumab Voxelotor, and L-Glutamine for sickle cell disease: effectiveness and value.Institute for Clinical and Economic Review 2021 Jun 23 https://icer-review.org/material/sickle-cell-disease-draft-evidence-report/
- Demirci S, Uchida N, Tisdale J. Gene therapy for sickle cell disease: an update. Cytotherapy. 2018;20(7):899–910.
- Hoban M, Orkin S, Bauer D. Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood. 2016;127(7):839–848.
- Basak A, Sankaran VG. Regulation of the fetal hemoglobin silencing factor BCL11A. Ann. N Y Acad Sci. 2016;1368(1):25–30.
- Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci USA. 2008;105(5):1620–1625.
- Xu J, Peng C, Sankaran VG, et al. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science. 2011;334(6058):993–996.
- Steinberg MH, Chui DH, Dover GJ, et al. Fetal hemoglobin in sickle cell anemia: a glass half full? Blood. Blood. 2014;123(4):481–485.
- Frangoul H, Altshuler D, Cappellini M, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-Thalassemia. N Engl J Med. 2021;384(3):252–260.
- Esrick E, Lehmann L, Biffi A, et al. Post-Transcriptional genetic silencing of BCL11A to treat sickle cell disease. . New England Journal of Medicine. 2021; 384: 205–215.
- Hsieh M, Bonner M, Pierciey F, et al. Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Adv. Blood Advances. 2020;4(9):2058–2063.
- Businesswire. bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111). Businesswire.com. Published 2021. 2021 Jul 1. https://www.businesswire.com/news/home/20210216005442/en/bluebird-bio-Announces-Temporary-Suspension-on-Phase-12-and-Phase-3-Studies-of-LentiGlobin-Gene-Therapy-for-Sickle-Cell-Disease-bb1111.
- bluebird bio. Bluebird bio provides updated findings from reported case of Acute Myeloid Leukemia (AML) in lentiglobin for Sickle Cell Disease (SCD) gene therapy program.; 2021. Accessed 2021 Jun 13. https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-provides-updated-findings-reported-case-acute.
- bluebird bio. bluebird bio Provides Update on Severe Genetic Disease Programs and Business Operations; 2021. 2021 May 30. https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-provides-update-severe-genetic-disease-programs-and.
- Jones R, DeBaun M. Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both or neither. Blood. 2021;doi: 10.1182/blood.2021011488.
- bluebird bio. bluebird bio announces the lifting of FDA clinical hold for sickle cell disease and β-Thalassemia Studies.; 2021. Accessed 2021 Jun 13. https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-provides-updated-findings-reported-case-acute
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). (2018 Feb 13).). Gene transfer for sickle cell disease. Identifier NCT03282656, http://clinicaltrials.gov/ct/show/NCT03282656?order=1
- Kanter J, Tisdale J, Mapara M, et al. 365 improvements in health-related quality of life for patients treated with lentiglobin for sickle cell disease (bb1111) gene therapy. Poster presented at: American Society of Hematology Annual Meeting and Exposition; December 6; Virtual Meeting. https://ash.confex.com/ash/2020/webprogram/Paper136193.html .
- Harrison C. First gene therapy for β-thalassemia approved. Nat Biotechnol. 2019;37(10):1102–1103.
- Coquerelle S, Ghardallou M, Rais S, et al. Innovative curative treatment of beta thalassemia: cost-efficacy analysis of gene therapy versus allogeneic hematopoietic stem-cell transplantation. Hum Gene Ther. 2019;30(6):753–761.
- Arnold S, Brazauskas R, He N, et al. Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. Haematologica. Haematologica. 2017;102(11):1823–1832.
- Saraf S, Ghimire K, Patel P, et al. Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease. PLoS One. PloS one. 2020;15(2):e0229710.
- Ouyang W, Dong G, Zhao W, et al. Restoration of β-globin expression with optimally designed lentiviral vector for β-thalassemia treatment in Chinese patients. Hum Gene Ther. 2020; 10.1089/hum.2020.204.
- Neumann PG, Sanders GD, Russell LB, et al. Cost-effectiveness in health and medicine. 2nd ed. New York NY: Oxford University Press; 2017.
- Woods B, Revill P, Sculpher M, et al. Country-level cost-effectiveness thresholds. Initial Estimates and the Need for Further Research. Value in Health. 2016;19:929–935.
- Salcedo J, Bulovic J, Young C. Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease. . Sci Rep. 2021;11. 10.1038/s41598-021-90405-1
- 2020 Value Assessment Framework Proposed Changes. Institute for Clinical and Economic Review; 2019. 2021 May 30. https://icer.org/wp-content/uploads/2020/10/ICER_2020_VAF_Proposals_082119-1.pdf .
- Garrison L, Jackson T, Paul D, et al., Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold. J Manag Care Spec Pharm. 2019;25(7):793–799.
- DeMartino P, Haag MB, Hersh AR, et al. A budget impact analysis of gene therapy for sickle cell disease: the medicaid perspective. . JAMA Pediatr. published online 2021 Mar 22 10.1001/jamapediatrics.2020.7140
- Salzman R, Cook F, Hunt T, et al. Addressing the value of gene therapy and enhancing patient access to transformative treatments. Mol Ther. 2018;26(12):2717–2726.
- Drummond M, Neumann P, Sullivan S, et al. Analytic considerations in applying a general economic evaluation reference case to gene therapy. Value Health. 2019;22(6):661–668.
- Clinicaltrials.gov. Bone marrow transplantation vs standard of care in patients with severe sickle cell disease (BMT CTN 1503). Betheseda, MD: National Library of Medicine; 2016. https://clinicaltrials.gov/ct2/show/NCT02766465. (Accessed: May 25, 2021). NLM identifier: NCT02766465.
- Clinicaltrials.gov. STRIDE Biorepository. Bethesda, MD: National Library of Medicine. 2017; https://clinicaltrials.gov/ct2/show/NCT02843347. (Accessed May25, 2020). NLM Identifier: NCT02843347.
- Gene OP. Therapy for sickle cell disease—a debt to be paid. JAMA Pediatr. 2021;175(6):565.